IsoTis and GenSci Orthobiologics Complete Merger

The two merging firms have already completed the integration of sales and marketing functions. They believe that the orthobiologic market sector is a fast-growing segment of the orthopedics market, driven in large part by an aging, increasingly active population. The new company combines expertise in natural bone grafts, synthetic bone graft substitutes, carrier technologies, and growth factors. A large distribution network will provide a foundation for North American growth, while an offering of leading edge technologies will help fuel expansion of the highly fragmented European and international markets.

"We have a strong product range on the market with substantial distribution power; we have a near-term pipeline and the development expertise to keep introducing new orthobiologics solutions; we have access to one of the world's largest research groups in our field to fuel long-term growth; and we have the organization and the financial resources to put the company on a steep growth curve in the years to come,” said Jacques Essinger, CEO of the new company.




Related Links:
IsoTis